Pfizer, Starboard

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...
STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...
There's some rumbling going on within Pfizer's investment community, as an activist hedge fund says that the company's ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...
Pfizer's Q3 consensus estimate is likely to be exceeded. Despite the underperformance over the past two months, see why PFE ...
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.